Tags : Early

Fitbit Reports Results of its COVID-19 Study for Early Detection

Shots: In May’2020, Fitbit has launched its COVID-19 study to build an algorithm that detects COVID-19 before symptoms starts. The study has enrolled 1000+ positive patients across the US and Canada is now delivering its first, preliminary results 90 days later The study demonstrated that its devices could detect ~50% of COVID-19 cases one day […]Read More

AstraZeneca to Initiate Production of its COVID-19 Vaccine Early in

Shots: AstraZeneca collaborates with the Mexican and Argentinean governments to initially produce 150M doses of the vaccine and eventually make at least 400M for distribution throughout the region The price for the vaccine is not final but it is expected not to exceed $4/ dose. The vaccine will initially supply to all Latin American countries […]Read More

Samsung Bioepis Launches Ontruzant (trastuzumab, biosimilar) for Early and Metastatic

Shots: The company launches its first oncology treatment Ontruzant (trastuzumab), a biosimilar referencing Herceptin in Brazil. The biosimilar has received ANVISA’s approval for the treatment of metastatic HER2-overexpressing BC, early HER2-overexpressing BC, and advanced gastric cancer Ontruzant is being supplied to SUS through a PDP b/w Samsung Bioepis & Bionovis and Bio-Manguinhos. This the second […]Read More

Celltrion and Teva Report Results Updated Results of CT-P6 in

Shots: The study involves assessing of CT-P6 vs reference trastuzumab in 516 patients neoadjuvant period of the study entered the adjuvant treatment period The study resulted in 9 patients (3.3%) in the biosimilar group and 6 patients (2.2%) in the reference group in the ITT population had recurrent or progressive disease @1 year. In adjuvant […]Read More

Roche Discontinues P-III CREAD-1 and 2 Trials of Crenezumab in

Shots: The P-III CREAD-1 and 2 study involves assessing of Crenezumab vs PBO in 1500 patients with early AD with confirmed evidence of cerebral beta-amyloid pathology (CSF or amyloid PET) for a duration of two years The discontinuation process of trial is based on its unmet 1EPs results from baseline Clinical Dementia Rating-Sum of Boxes […]Read More

Samsung Bioepis’ Biosimilar Transtuzumab Ontruzant (transtuzumab,dttb), Receives US FDA Approval

Shots: The US FDA has approved Ontruzant for all eligible indication vs reference Herceptin(transtuzumab), for adjuvant treatment of HER2-overexpressing breast cancer, metastatic breast cancer and metastatic gastric cancer or gastroesophageal junction adenocarcinoma in patients not received prior treatment for metastatic disease The approval is based on clinical study results assessing Ontruzant vs Herceptin in 367 […]Read More

NTU SingaporeTTSH Develops AI based Smart Medical Device for Early

Shots: The medical device resembles to a stethoscope and has shown results demonstrating 92% accuracy in identifying patients with Congestive Heart Failure compared to current methods i.e. X-ray, CT scans The non-invasive device with AI sensors placed on chest or back, enables early detection of excess fluid in lungs within 10 seconds, when attached to […]Read More